Guggenheim Forecasts Strong Price Appreciation for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock

Key Points

• Guggenheim raised its price target for Damora Therapeutics (NASDAQ: DMRA) from $40 to $60 and maintained a “buy” rating, implying approximately 196% upside from the reported $20.27 share price.
• Analyst sentiment is broadly positive, with MarketBeat reporting a consensus “Buy” rating and an average price target of $46.50, although ratings range from “strong buy” to “sell.”
• Damora reported quarterly EPS of -$0.39, beating the consensus estimate of -$0.45; institutional investors own 14.2% of the company, including recent purchases by Braidwell and Seven Fleet Capital Management.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) had its target price upped by research analysts at Guggenheim from $40.00 to $60.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price objective indicates a potential upside of 196.00% from the stock's current price.

Other analysts have also issued research reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, August 24th. Wedbush lifted their price target on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an "outperform" rating in a research note on Thursday, July 30th. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a "buy" rating and a $50.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA opened at $20.27 on Friday. The company's fifty day moving average is $28.64 and its two-hundred day moving average is $26.38. Damora Therapeutics, Inc. Common Stock has a 52-week low of $3.50 and a 52-week high of $38.33. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -6.01 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. As a group, sell-side analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of large investors have recently bought and sold shares of DMRA. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $303,000. Arizona State Retirement System acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $260,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $7,398,000. Finally, Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $42,146,000. 14.20% of the stock is currently owned by institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.